Efficacy of lapatinib in therapy-resistant HER2-positive circulating tumor cells in metastatic breast cancer

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Agelaki, Sofia ^a,b   Kalykaki, Antonia ^a   Markomanolaki, Harris ^b   Papadaki, Maria A ^b   Kallergi, Galatea ^b   Hatzidaki, Dora ^a   Kalbakis, Kostas ^a   Mavroudis, Dimitrios ^a,b   Georgoulias, Vassilis ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; IMMUNOFLUORESCENCE MICROSCOPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PARONYCHIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; POSTMENOPAUSE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL COUNT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PREMENOPAUSE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR EMBOLISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL COUNT; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; POSTMENOPAUSE; PREMENOPAUSE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84939196919     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123683     Document Type: Article

References (38)

1. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, et al. (2008) Systemic spread is an early step in breast cancer. Cancer Cell 13: 58-68. doi: 10.1016/j.ccr.2007.12.003 PMID: 18167340
2. Ignatiadis M, Georgoulias V, Mavroudis D (2008) Circulating tumor cells in breast cancer. Curr Opin Obstet Gynecol 20: 55-60. doi: 10.1097/GCO.0b013e3282f22b2e PMID: 18197007
3. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802. PMID: 16120859
4. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, et al. (2002) Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 20: 3404-3412. PMID: 12177100
5. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, et al. (2006) Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. J Clin Oncol 24: 3756-3762. PMID: 16769987
6. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, et al. (2009) Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 101: 589-597. doi: 10.1038/sj.bjc.6605183 PMID: 19623181
7. Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, et al. (2012) Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer 106: 1917-1925. doi: 10.1038/bjc.2012.202 PMID: 22669159
8. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, et al. (2011) Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res 17: 7183-7193. doi: 10.1158/1078-0432.CCR-11-0981 PMID: 21976532
9. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791. PMID: 15317891
10. Lianidou ES, Markou A (2011) Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 57: 1242-1255. doi: 10.1373/clinchem.2011.165068 PMID: 21784769
11. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 7: e33788. doi: 10.1371/journal.pone.0033788 PMID: 22586443
12. Meng S, Tripathy D, Shete S, Ashfaq R, Haley B, et al. (2004) HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 101: 9393-9398. PMID: 15194824
13. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, et al. (2011) mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin Cancer Res 17: 3600-3618. doi: 10.1158/1078-0432.CCR-11-0255 PMID: 21505063
14. Munzone E, Nole F, Goldhirsch A, Botteri E, Esposito A, et al. (2010) Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. Clin Breast Cancer 10: 392-397. doi: 10.3816/CBC.2010.n.052 PMID: 20920984
15. Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, et al. (2007) Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 9: R74. PMID: 17963511
16. Alix-Panabieres C, Pantel K Circulating tumor cells: liquid biopsy of cancer. Clin Chem 59: 110-118. doi: 10.1373/clinchem.2012.194258 PMID: 23014601
17. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, et al. (2009) Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Breast Cancer Res Treat 117: 525-534. doi: 10.1007/s10549-008-0239-3 PMID: 19016323
18. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, et al. (2008) Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Breast Cancer Res 10: R80. doi: 10.1186/bcr2149 PMID: 18822183
19. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, et al. (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 27: 2177-2184. doi: 10.1200/JCO.2008.18.0497 PMID: 19332733
20. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, et al. (2007) Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Ann Oncol 18: 1623-1631. PMID: 17515404
21. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, et al. (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12: 4218-4224. PMID: 16857794
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216. PMID: 10655437
23. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, et al. (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10: 8152-8162. PMID: 15623589
24. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, et al. (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23: 1420-1430. PMID: 15735118
25. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, et al. (2008) Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 13: 838-844. doi: 10.1634/theoncologist.2008-0048 PMID: 18650259
26. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, et al. (2001) Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141-1146. PMID: 11481385
27. Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, et al. (2011) HER2-positive circulating tumor cells in breast cancer. PLoS One 6: e15624. doi: 10.1371/journal.pone.0015624 PMID: 21264346
28. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, et al. (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res 14: 2593-2600. doi: 10.1158/1078-0432.CCR-07-4758 PMID: 18451221
29. Wulfing P, Borchard J, Buerger H, Heidl S, Zanker KS, et al. (2006) HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res 12: 1715-1720. PMID: 16551854
30. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, et al. (2004) Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 10: 8185-8194. PMID: 15623593
31. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, et al. (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9: 1489-1502. doi: 10.1158/1535-7163.MCT-09-1171 PMID: 20501798
32. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743. PMID: 17192538
33. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, et al. (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359: 366-377. doi: 10.1056/NEJMoa0800668 PMID: 18596266
34. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, et al. (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26: 1066-1072. doi: 10.1200/JCO.2007.13.9949 PMID: 18212337
35. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, et al. (2012) Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat 134: 283-289. doi: 10.1007/s10549-012-2045-1 PMID: 22476856
36. Stebbing J, Payne R, Reise J, Frampton AE, Avery M, et al. (2013) The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One 8: e62543. doi: 10.1371/journal.pone.0062543 PMID: 23667487
37. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. (2006) Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403-6409. PMID: 17085652
38. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, et al. (2012) Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 23: 1744-1750. doi: 10.1093/annonc/mds020 PMID: 22377561